In CRC, the levels of SIRT4 are decreased compared with normal colon tissue, and its lower levels are associated with worse prognoses and lower survival rates in patients, while SIRT4 overexpression inhibits CRC cell proliferation in vitro and in vivo, inhibiting glutamine metabolism and glycolysis [32,34]. The gene discussed is SIRT4; the disease is colorectal carcinoma.